Autologous Transplantation of Lentivector/Acid Ceramidase–Transduced Hematopoietic Cells in Nonhuman Primates
- 31 January 2011
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 22 (6) , 679-687
Abstract
Farber disease is a rare lysosomal storage disorder (LSD) that manifests due to acid ceramidase (AC) deficiencies and ceramide accumulation. We present a preclinical gene therapy study for Farber disease employing a lentiviral vector (LV-huAC/huCD25) in three enzymatically normal nonhuman primates. Autologous, mobilized peripheral blood (PB) cells were transduced and infused into fully myelo-ablated recipients with tracking for at least 1 year. Outcomes were assessed by measuring the AC specific activity, ceramide levels, vector persistence/integration, and safety parameters. We observed no hematological, biochemical, radiological, or pathological abnormalities. Hematological recovery occurred by approximately 3 weeks. Vector persistence was observed in PB and bone marrow (BM) cells by qualitative and quantitative PCR. We did not observe any clonal proliferation of PB and BM cells. Importantly, AC-specific activity was detected above normal levels in PB and BM cells analyzed post-transplantation and in spleens and livers at the endpoint of the study. Decreases of ceramide in PB cells as well as in spleen and liver tissues were seen. We expect that this study will provide a roadmap for implementation of clinical gene therapy protocols targeting hematopoietic cells for Farber disease and other LSDs.Keywords
This publication has 27 references indexed in Scilit:
- In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber diseaseMolecular Genetics and Metabolism, 2008
- Anti-CD25 Targeted Killing of Bicistronically Transduced Cells: A Novel Safety Mechanism Against Retroviral GenotoxicityMolecular Therapy, 2007
- Engineered Human tmpk/AZT As a Novel Enzyme/Prodrug Axis for Suicide Gene TherapyMolecular Therapy, 2007
- Multiple Reduced-intensity Conditioning Regimens Facilitate Correction of Fabry Mice After Transplantation of Transduced CellsMolecular Therapy, 2007
- Farber's disease without central nervous system involvement: bone-marrow transplantation provides a promising new approachAnnals of the Rheumatic Diseases, 2006
- Successful hematopoietic stem cell transplantation in farber diseaseThe Journal of Pediatrics, 2004
- Real-Time Quantitative Reverse Transcriptase-Polymerase Chain Reaction as a Method for Determining Lentiviral Vector Titers and Measuring Transgene ExpressionHuman Gene Therapy, 2003
- Molecular Evidence of Lentiviral Vector-Mediated Gene Transfer into Human Self-Renewing, Multi-potent, Long-Term NOD/SCID Repopulating Hematopoietic CellsMolecular Therapy, 2002
- Marking and Gene Expression by a Lentivirus Vector in Transplanted Human and Nonhuman Primate CD34+CellsJournal of Virology, 2000
- Long‐term outcome of Hurler syndrome following bone marrow transplantationAmerican Journal of Medical Genetics, 1993